GeoVax Labs, Inc.
GOVX
Positions held
Your positionsGOVX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $2.90M | Enterprise value | -$708,255 | Trailing P/E | — | Forward P/E | -0.33 |
| PEG | — | Price / book | 1.20 | Beta | 3.69 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -8.9% | ROA | -2.6% | Debt / equity | 0.18 |
| Current ratio | 1.54 | Free cash flow | -$10.82M | Analyst recommendation | none | Mean target | $10.00 |
| 52w high | $15.75 | 52w low | $0.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.9M | — |
| Op margin | — | — | — | — | -635.8% | — |
| Net income | -$4.4M | -$5.3M | -$4.4M | -$6.3M | -$5.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.4M | -$5.3M | -$4.4M | -$6.4M | -$5.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.5M | $4.0M | $0.0M | $0.1M | — |
| Op margin | -869.3% | -635.8% | — | -17207.5% | — |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
2026-09-29 · GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
2026-09-21 · GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
2026-09-16 · GeoVax Confirms Bundibugyo Ebola Vaccine Construct
2026-09-14 · GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
2026-09-10 · GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
2026-08-26 · GeoVax Announces a Warrant Inducement Transaction
2026-08-25 · GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
2026-08-24 · GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies
2026-08-20 · GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
Price (daily)
Full chart · RSI · MACD · patterns